Introduction
Heat shock proteins (HSP) are molecules with highly conserved structures, that have been shown to participate in protein quality control in archaea, eubacteria and eukaryotes [1, 2] . They are thus presumably derived from precursor genes already existing in the last universal common ancestor (LUCA) [3] . HSPs were first characterized as proteins that are induced abundantly in cells exposed to a variety of stresses-most notably heat shock itself [1, 4] . As their function was unknown at the time of discovery, the HSPs were named according to their molecular weights. The 70 kilodalton HSP thus became known as Hsp70. Hsp27, 40, 60, 70, 90 and 110 were soon discovered and each of these were found to be members of a distinct protein family [1] . These proteins have been renamed recently as HSPB, DNAJ, HSPD, HSPA, HSPC and HSPH [5] . HSP family members evidently underwent multiple duplication events early in evolution, and there are, for instance, at least 12 HSP70 family members in both yeast and human, as well as at least 30 pseudogenes related to human HSP70 [5, 6] . The existence of multiple members of the HSP gene families may have permitted the emergence of variant physiological functions in some members [6] . As will be discussed below, such potential heterogeneity in the repertoires of HSP paralogues, within individual families, may be of particular significance in cancer and in the design of cancer therapeutics.
During intracellular molecular chaperone reactions, each of the HSP families participates in folding the proteome, exhibiting subtly different properties and functions and permitting stepwise modelling of protein tertiary structures toward active, native forms [1, 2, 7, 8] . Thus, in healthy tissues, newly synthesized proteins can attain their genetically programmed function and polypeptides & 2017 The Author(s) Published by the Royal Society. All rights reserved.
that become unfolded can be refolded and resume their intracellular activities. The HSP families appear also to operate in relay in some circumstances. For instance, Hsp27 (HSPB1) can form high molecular complexes that associate with unfolded clients and prevent their aggregation [7] . These rescued proteins are in turn passed on to Hsp70 for further folding and then to Hsp90 to achieve the fully native structure [2, 9] . The two key chaperones Hsp70 and Hsp90 also require assistance of dedicated cofactors that aid in the mechanisms of intracellular protein folding and can also couple each of these HSPs to other proteins that may coordinate the proteotoxic stress response (table 1) [18] . Co-chaperones could potentially offer multiple alternative targets in cancer therapy (not discussed here, but reviewed in: [18] ).
Protein unfolding within the cell triggers the induction of the powerful homeostatic heat shock response, in which abundant quantities of HSPs are made [4] . The rapid synthesis of HSPs is primarily a result of a sequence-specific transcription factor-heat shock factor 1 (HSF1) being switched on by the proteotoxic stress, resulting in active transcription of the whole cohort of HSP genes [19] . Intracellular HSF1 regulation is maintained on knife-edge balance, with opposing mechanisms for induction and repression, and loss of effective homeostatic control contributing to a range of pathologies, including cancer, protein-folding disorders such as Alzheimer's disease as well as some of the symptoms of aging [20] [21] [22] . In this review, we will concentrate on factors underlying disruption of HSP regulation in cancer.
An extracellular role for heat shock proteins in tumour formation
It is now widely accepted that multidomain proteins may have more than one cellular function and may populate more than one location in cells. Thus, in addition to the chaperoning of intracellular clients, HSPs are now known to play significant roles in cell physiology and pathology as extracellular signalling ligands [23] [24] [25] . For instance, free Hsp70 released from dying cells into the tissue milieu has been shown to trigger inflammatory responses in macrophages after binding to receptors. Extracellular HSPs can thus play somewhat controversial roles in immune and inflammatory responses as 'danger signals' after binding to receptors on monocytes, macrophages and dendritic cells [12, 26] . However, at this moment, dedicated high-affinity receptors have not been found for any of the HSPs. A number of acceptor proteins that were previously shown to recognize multiple potential ligands do, however, interact with the HSPs [27] . These proteins include the scavenger receptors LOX1, SREC-I and FEEL-1, the LDL receptor LRP1/CD91 and the largely immunosuppressive sialic acid-binding proteins (Siglec receptors) [13, 27, 28] . The possession of multiple receptors, which also can bind a range of other, unrelated physiological ligands, makes for a complex response to extracellular HSPs, depending on cell type and surface density of individual receptors. It appears that HSPs can also be released from undamaged cells, even though HSPs in general lack the leader sequences characteristic of secreted proteins [29] . Thus, the canonical endoplasmic reticulum (ER)-Golgi route of secretion is denied them. Leaderless proteins are, however, capable of secretion by non-canonical mechanisms. These processes are exemplified by mechanisms involved in release of cytokines such as interleukin 1 beta. This cytokine, lacking a leader sequence, employs a number of non-canonical routes for secretion, including release through secretory lysosomesreviewed in [29] . Hsp70 is secreted from prostate carcinoma cells through such a route along with accompanying lysosomal marker proteins [23, 30] . In addition to being secreted in free form, Hsp70 and other HSPs can also be released from cells within vesicular structures known as exosomes, and in this form, can exert a range of inflammatory or immunosuppressive effects, depending on the nature of target cells [16, 17, 31] . It may be significant that the HSPs appeared to be present on the surfaces of exosomes rather than being carried in the lumen, and the exposed portion of the HSP thus had the potential to interact with acceptor proteins of unknown nature on target cells [31] . As may be apparent, therefore, the extracellular properties of HSPs are highly complex and often unpredictable, may involve multiple cell and receptor types and are as yet not completely understood [12] . In addition to participating in immune and inflammatory responses, key extracellular roles for some of the chaperones are emerging in studies of cancer, metastasis and wound repair, as will be discussed below [32] [33] [34] .
Intracellular heat shock proteins and cancer
Intracellular HSPs-most notably Hsp27, Hsp72 (the combined product of the HSPA1A and HSPA1B genes) and Hsp90 (product of the HSPC2 and HSPC3 genes)-have been shown to accumulate to high levels in many types of cancer [35] [36] [37] . Although the mechanisms underlying these increases are not fully understood, it has been suggested that HSPs proliferate in cancer cells in response to folding stresses that arise during malignant transformation and tumour progression [38] . The accumulation of oncogenic proteins, many of them mutated and with the fragile, flexible structures that often accompany strong enzymatic activity, demands an increase in protein folding power [38, 39] . As molecular chaperones operate in a stoichiometric manner, often associating in long-lived protein complexes with unstable clients, in contrast to enzymes that operate in a hit-and-run catalytic manner, large intracellular concentrations of HSPs are required for effective folding [2] . It has been envisaged that this increase in folding demand in cancer in turn triggers the heat shock response, leading to HSF1-dependent increases in transcription of HSP genes [40] . Tumour cells have thus come to be regarded as 'addicted to chaperones', becoming dependent on a constant supply of large concentrations of HSPs, and responding with some distress to their withdrawal (figure 1) [9, 38, 41] . HSF1 may also be activated directly through its coupling to highly active cancer cell signalling pathways. For instance, in mammary carcinoma cells HSF1 is activated and Hsp70 is synthesized through a mechanism controlled downstream of the oncogene Her2 [42] . However, the outcome in terms of chaperone accumulation would be similar whether induced by increased folding demand or through an oncogenic signalling cascade. HSPs have been shown to be actively involved in many of the key mechanisms that drive malignant transformation and tumour progression, including, stimulus-independent growth, escape from apoptosis and senescence, de novo angiogenesis, invasion of surrounding tissues and metastasis [10, 11, [43] [44] [45] [46] [47] [48] of the Polyoma middle T antigen, Hsp72 inactivation did not trigger the senescence of the tumour cells or markedly reduce primary tumour growth, but instead prevented invasion and metastasis of the cancer cells [45] . Hsp72 is thus a significant protein in tumorigenesis and may play multiple roles as a facilitator of cancer cell properties, its function depending on the nature of the driver oncogene [45, 49] . Such experiments have not to our knowledge been performed in Hsp27 and Hsp90 knockout mice, although one anticipates such crucial studies in future experiments. Reducing Hsp90 and Hsp70 activity in 'chaperone-addicted' cancer cells by inhibitory compounds can lead to the loss of a wide array of oncogenic proteins, decreased tumour cell growth and death [9, 38, 50] . Pharmacological targeting of intracellular Hsp90 in particular has thus become a major academic focus and commercial venture due to the possibilities of destabilizing multiple oncogenic proteins in tumour cells [9] . This approach is highly desirable in circumventing the problems associated with single-target chemotherapeutic agents. Such problems are mainly the result of development of tumour cell resistance to the single agent due to mutations in the target oncogene or through switching to alternative pathways to bypass the molecule targeted in therapy [51] . Hsp90 in particular is also an appealing target in cancer therapy due to its role as a capacitor of evolutionary processes [52] . Evolution of treatment resistance is a major mechanism for loss of response to pharmacological agents, and Hsp90 inhibitors could potentially reduce the impact of this process [53] [54] [55] . In addition, there are data to suggest that intracellular Hsp90 may be intrinsically more sensitive to the drugs compared to the chaperone when residing in normal cells [50] . The basis for this difference is not clear although it could involve posttranslational modifications (PTMs) specific to some cancers [50] . Mapping of the sites of significant PTMs in Hsp90 is at an early stage, although some important residues have been discovered [56, 57] . The drawbacks to Hsp90-based chemotherapy encountered with the currently tested drugs appeared to be mainly twofold. Firstly, all tissues require continuous molecular chaperone activity to ensure the folding of key client proteins, and thus to carry out their differentiated functions and maintain vigour [9, 38] . Drugs that inhibit the activities of whole families of HSPs-such as is the case in Hsp90-targeted therapy-may produce normal tissue complications at the concentrations required for inhibiting Hsp90 and thus limit success in clinical trials [54] . Performance of current Hsp90 drugs in clinical trials thus seemed less promising than could be anticipated from the earlier experiments carried out in tissue culture (reviewed by [14] ). Secondly, HSF1 is known to be regulated through feedback repression by high levels of both Hsp70 and Hsp90 [40] . HSP-targeting drugs could thus activate HSF1 through de-repression, lead to transcription of the whole HSP cohort and may increase intracellular chaperoning potential through increasing levels of non-inhibited chaperones; these effects are thus likely to confound the tumoricidal effects of the drugs at source [15, 58] . HSF1 can be regulated by feedback inhibition through both Hsp70 and Hsp90, and increased expression of either chaperone represses the factor [59] . Thus, targeting Hsp90 or Hsp70 may have the confounding effect of inducing Hsp70 or Hsp90 and fostering tumorigenesis and treatment resistance. However, these are still relatively early days for the HSP drug field, and efforts are being made to surmount these difficulties by imaginative approaches to drug design.
One way to mitigate drawback 1 could involve targeting individual members of the HSP families. As discussed above, each of the HSP gene families appears to have multiple members originating from the duplication of common ancestors. There are for instance as many as 17 members of the HSP70 family, four HSP90 members and 10 members of the 'small HSPB' family, of which Hsp27 is a member [6, 37, 60, 61] . Gene duplication permits the evolution of new properties in some of the family members, and such appears to be the case with the HSPs. With the HSP70 family for instance, the specific targeting of Hsp72 by the drugs pifithrin-mu or methylene blue inhibited activity of this chaperone with some specificity and could play a potential role in cancer therapy that would spare normal tissues [62, 63] . Hsp72 is expressed at high levels only in cancer cells and heat shocked normal cells, and thus one would not envisage excessive toxicity in targeting this chaperone, due to the presence in the cells of a constitutive HSP70 family member Hsc70 (HSPA8). This protein is present at high levels in all cells and is able to meet the molecular chaperone needs of such cells [8] . Mammary cancer cells appear to require the inducible Hsp72 to protect against cell senescence and to invade and metastasize, and are thus sensitive to Hsp72 inhibition [45, 49] . Hsp90-alpha (HSPC2) is a non-essential gene with some different properties compared to those of the other cytoplasmic paralogue Hsp90-beta (HSPC3), and it may be possible to target this chaperone with some specificity as with Hsp72 [61, 64] . Getting around drawback 2 (chaperone induction by de-repression of HSF1) would probably require a better understanding of HSF1 regulation (whose properties are not fully understood even now) and carefully selected drugs that might be designed to inhibit HSP activity but not lead to HSF1 induction.
Extracellular Hsp90: a novel role in cancer aetiology
As mentioned above, HSPs can be release into the extracellular spaces and may influence the properties of cells they encounter [12, 13, 28] . Properties of extracellular Hsp90 have been carefully characterized in studies of wound healing. It was shown that that Hsp90-alpha secreted from keratinocytes could mediate effective wound healing through binding to surface receptors [24, 32] . Hsp90 has been shown in a number of studies to interact with at least two acceptor proteins on the cell surface, including the extracellular protease matrix metalloprotein 2 (MMP2), a key factor in progression of many cancers, and the LDL receptor LRP1 [14, 65] . These effects were mediated mainly by Hsp90-alpha an Hsp90 paralogue that is readily secreted, while the other cytoplasmic form of Hsp90, Hsp90-beta, remained largely intracellular [32] . Binding of Hsp90-alpha was shown in some studies to trigger a transmembrane signal cascade initiated by LRP1 and transmitted by the serine/threonine kinase Akt [66] . These effects of extracellular Hsp90 in wound healing appeared to be mediated mainly by increasing the mobility properties of cells within the wound [14] . As some of the properties of growing tumours in some ways resemble those of an unhealable or unhealing wound, similar studies have been carried out in cancer [67] . Proteomic studies had suggested a role for extracellular Hsp90 in cancer invasiveness [68] . More recently it was shown that rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 373: 20160524 extracellular Hsp90 could trigger prostate tumour growth, in this case through sustained activation of the MEK/ERK pathway [33] . In addition, extracellular Hsp90 could trigger a morphological change-epithelial mesenchymal transition (EMT)-a cellular transformation that was associated with loss of the epithelial marker E-cadhedrin [34] . Hsp90-induced EMT was associated in these investigations with increased invasiveness of the cancer cells, a continuing theme with studies of extracellular Hsp90. In addition, extracellular Hsp90 also promoted prostate cancer stem cell (CSC) heterogeneity [34] . As CSCs are associated with invasion, metastasis, tumour repopulation and treatment resistance, extracellular Hsp90 may be playing an important role in tumour progression through this mechanism [45, 69] . Extracellular Hsp90 appears also to participate in the remodelling of the extracellular matrix (ECM) through its interaction with MMP2 and MMP9, another important process in the invasion of surrounding tissues and metastasis by tumour cells [70] . Binding of Hsp90 appears to activate the pro-forms of these enzymes through their proteolytic cleavage, release active MMPs and thus permit ECM remodelling and enhanced invasion [71, 72] . By contrast, there are few reports that describe the roles of extracellular Hsp70 in the properties of tumour cells, although recent studies showed that recombinant Hsp70 from Arabidopsis could sustain viability, activate MMPs and stimulate migration in human mammary cells [73] . Additional reports also indicated that extracellular Hsp27 could exert pro-angiogenic effects in cancer through stimulation of transcription of the vascular endothelial growth factor (VEGF) gene [74] . For a detailed review on the properties of extracellular Hsp27 readers are referred to reference [25] .
Hsp70 and other HSPs have also been shown to accumulate at the surface of tumour cells [75] [76] [77] . Such surface-associated HSPs may influence sensitivity to therapy [78] . It is not clear which mechanisms are involved in association of these proteins, which lack an obvious membrane-spanning domain, with the plasma membrane. Hsp70 detected at the cell surface may be the result of extracellular chaperone binding to surface receptors or could be due to an ability of the protein to incorporate in membranes by non-canonical mechanisms [30, 79] .
In summary, therefore, there is a growing body of evidence that indicates a significant role for extracellular HSPs in the aetiology of a number of cancers, with most of the recent work emphasizing hsp90-alpha. Although we have concentrated here on HSPs secreted from cells into the extracellular spaces, both Hsp70 and Hsp90 have also been found stably associated with the cell surface as mentioned above, and these forms of extracellular HSP may also play significant roles in cancer [80, 81] . Study of extracellular HSPs in cancer is a new and very rapidly advancing field and many new concepts and paradigms are expected to emerge in the next few years.
5. The significance of intracellular heat shock proteins and extracellular heat shock proteins in cancer therapy?
The findings discussed above have clear implications for cancer treatment and provoke the question: to what degree do the available chaperone targeting drugs interact with intracellular Hsp90 or extracellular Hsp90? Most Hsp90-targeting agents used so far were prepared under the assumption of inhibiting intracellular chaperones in cancer cells and the folding of proteins in the cytoplasm essential for transformation [15] . These questions are most significant for Hsp90 studies, in which the inhibitory drugs have undergone several series of largely inconclusive clinical trials [54] . As mentioned earlier, the design of drugs directed at intracellular Hsp90 would preferably attempt to overcome the problems of normal tissue toxicity due to the agents targeting both Hsp90-alpha and Hsp90-beta. In addition, it would appear that membrane-impermeable Hsp90 drugs, such as 17-AAG linked to beads and DMAG-N-oxide, could inhibit the activity of extracellular Hsp90 alpha, and thus some of the positive results with the soluble forms of the drugs observed in earlier studies may have involved effects of the agents in both compartments [68, 82] . This was an unanticipated finding as these drugs are thought to function by competitively inhibiting the binding of ATP to the ATPase domain of Hsp90, and only low levels of extracellular ATP are observed in the vicinity of most cells [81] . In addition, the domain in Hsp90-alpha responsible for stimulating cell mobility has been mapped to a small polypeptide region known as F5, which is distant from the ATPase domain [83] . While the F5 peptide stimulated cell migration in a manner independent of a non-permeable form of Hsp90 inhibitor geldanomycin (NPGA), the activity of full-length Hsp90-alpha was inhibited by exposure to NPGA [83] . It is thus difficult to distinguish the relative importance of intracellular and extracellular Hsp90 in studies measuring responses to HSP90-targeting drugs. The major tumorigenic property of extracellular Hsp90-alpha appears to be the stimulation of cell migration within tissues and tumours [14, 34, 81] . However, intracellular Hsp90 possesses many additional properties within the cytoplasm and nucleus that are important in the malignant phenotype, and it would thus seem unlikely that we could overlook intracellular Hsp90 as a target in cancer [9, 84] .
6. Conclusion-optimizing heat shock proteinbased approaches to cancer therapy
The requirement for protein folding appears to be a basic need for all cells to flourish [2] . Thus the ancestors of the mammalian HSPs appeared to have been expressed in the earliest cells (LUCA) that existed before the evolution of modern species [3] . Although the targeting of HSPs is an extremely attractive strategy in permitting the inactivation of a large fraction of the multiple proteins that conspire in tumorigenesis, inhibition of the functions of whole HSP families would seem to take aim at one of the activities essential for most types of life. Targeting these proteins is thus finely balanced between the agreeable outcome of eradicating malignant cells and the menace afforded to healthy normal tissues. However, at least in the case of Hsp90, tumour cells would seem to be selectively sensitive to inhibition of the chaperone, thus offering a window of vulnerability in terms of tumour treatment [50] . Future advances are likely to be knowledge based-involving a better understanding of Hsp90 alpha and beta structure-function relationships and regulation of the chaperone within the cell. Going hand in hand with these studies would be attempts to optimize the pharmacology and derive stable, water-soluble compounds that target key residues in Hsp90 with maximum potency and selectivity for cancer.
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Another potentially selective approach is to inhibit the activities of individual HSP family members that become more highly induced in cancer and may play specialized roles in malignant progression. For instance, Hsp72 is not expressed in most normal cells in which the constitutive paralogue Hsc70 is sufficient for basic levels of protein folding. However, Hsp72 is essential for many of the traits that lead to the emergence of cancers and tumours that either fail to emerge or grow only slowly in knockout mice [45, 49] . Although the HSP70 family members are remarkably well conserved, novel drugs are under development that could selectively target Hsp72. Similarly for the HSP90 family, Hsp90-beta is an essential gene and its knockout is embryo-lethal [85] . It is not surprising, therefore, that drugs targeting this protein could lead to some normal tissue toxicity. Hsp90-alpha is the stressinducible paralogue that becomes increased to high levels in cancer, but is not essential in mouse models [64] . This molecule would thus seem to offer more potential for selectivity as a target in cancer therapy.
As discussed above, Hsp90-alpha is also secreted by many cancers, where it is a potent activator of the invasion of surrounding tissues. It might thus be possible to inhibit the extracellular function of Hsp90-alpha selectively with cellimpermeable drugs or using blocking monoclonal antibodies. In addition, HSP70 family proteins have also been shown to be secreted from tumour cells, and extracellular Hsp72 may play similar roles in cancer as observed with Hsp90-alpha. Although this area has not been investigated in any depth, it provides a further approach to development of therapeutics that are selective for tumour HSPs.
The third of the trio of chaperones discussed here, Hsp27 differs from the others in lacking an ATPase domain, making drug design more complicated in the absence of an ATPbinding groove. However, promising studies using peptide aptamers to effectively target Hsp27 have been carried out in studies of this chaperone [86] . Extracellular Hsp27 has recently been shown to play an important role in oncogenesis and could be a future potential target in cancer therapy [74] .
Data accessibility. This article has no additional data. Competing interests. None of the authors have any conflicts of interest related to this study.
Funding. This work was supported by funding from NIH research grants: R01CA119045, RO1CA47407 and RO1CA176326.
